Short Sellers Run for Cover From Major Biotechs

Print Email

The short interest data are out for the April 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.

The April 29 short interest data have been compared with the previous report, and short interest moves were mixed in these selected stocks.

Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 7.36 million shares from the previous level of 8.85 million. Shares closed most recently at $157.24, in a 52-week trading range of $130.09 to $181.81.

Biogen Inc. (NASDAQ: BIIB) had its short interest decrease to 1.95 million shares from the previous level of 2.12 million. Shares closed Tuesday at $273.27, within a 52-week range of $242.07 to $420.99.


Celgene Corp. (NASDAQ: CELG) short interest for this settlement date decreased to 7.97 million shares from the previous 8.46 million. Shares closed most recently at $103.25, in a 52-week range of $92.98 to $140.72.

Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest increase to 28.07 million shares from 26.68 million in the previous period. Shares closed Tuesday at $86.18, in a 52-week trading range of $81.89 to $123.37.

MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 105.71 million shares. The previous reading was 103.74 million. Shares closed most recently at $0.95, in a 52-week trading range of $0.64 to $7.32.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest decreased to 5.56 million, compared to the previous level of 5.80 million. Shares closed most recently at $145.48, in a 52-week range of $124.16 to $208.88.